| |
Newsroom /
Industry
/
Industry
/
Primary Biliary Cirrhosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Primary Biliary Cirrhosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
The Primary Biliary Cirrhosis Therapeutics Market is Forecast to Show High Growth, The report identifies
the key trends shaping and driving the global primary biliary cirrhosis market.
Hyderabad,
AP,
India
(prbd.net)
13/06/2011
GlobalData has estimated the global primary biliary cirrhosis therapeutics market to be valued at $264m
in 2010. It is expected to grow to $445m with a Compound Annual Growth Rate (CAGR) of 7.8% by 2017.
This growth is primarily attributed to the increasing prevalence of the disease due to the increasing
awareness of the disease and early diagnosis. The diagnosis rate is also high in primary biliary cirrhosis
(PBC). Around 60% of patients are asymptomatic at the time of diagnosis. Ursodiol of Axcan Pharma
(Aptalis Pharma) is the only approved drug and the market is dominated by generics.
GlobalData’s analysis showed that there is only one molecule in the PBC pipeline. Since the pipeline is
weak with no promising drugs to be launched in the forecast period the pipeline is not expected to have
any impact on the market growth. INT-747 is the only molecule in the PBC pipeline. It is a farnesoid X
receptor (FXR) agonist. INT-747 treatment prevents, and even reverses, liver damage caused by
progressive fibrosis (scarring). Though the drug is a novel molecule and has disease-modifying properties
it will not have an impact in the forecast period because it is in only in Phase II of development.
For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Primary-Biliary-Cirrhosis-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017
GlobalData’s analysis found that the unmet need in the PBC market is low, which implies that the market is well-served with the current product options. However, the market holds promise for new entrants to the PBC market. This is because while ursodiol improves the biochemical indices of the patients it doesn’t reverse the disease. The response rate is also not high for ursodiol. It is more effective in the early stages than in the advanced stages. As a result the market needs new drugs with disease-modifying properties.
GlobalData, the industry analysis specialist, has released its new report, “Primary Biliary Cirrhosis
Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source
of information and analysis on the global primary biliary cirrhosis therapeutics market. The report identifies the key trends shaping and driving the global primary biliary cirrhosis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global primary biliary cirrhosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Primary-Biliary-Cirrhosis-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017
Visit our report store: http://www.globaldata.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|